medigraphic.com
ISSN 2078-7170 (Electronic)

2013, Number 4

<< Back Next >>

CorSalud 2013; 5 (4)

High-density lipoproteins: vascular guards against atherosclerosis

Ponce GY, Ponce GA, Rodríguez LA, Llanes ÁC

Language: Spanish
References: 66
Page: 366-378
PDF size: 1104.81 Kb.


ABSTRACT

Increasing levels of high-density lipoproteins and their potential benefits in Atherosclerosis motivated us to write this article in order to update knowledge on this topic. The structure of these lipoproteins is described, as well as their atheroprotective vascular effects and the reverse cholesterol transport. New strategies to increase their concentration in the body are presented, as recent studies indicate that they stabilize atherosclerotic plaques in an expedited manner. Therefore, it constitutes a novel therapeutic alternative in high risk patients. This will update the knowledge on high-density lipoproteins, in order to provide a better quality care in the prevention, control and treatment of this common disease.


REFERENCES

  1. Badimón L, Vilahur G. Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaque-tario. Rev Esp Cardiol. 2008;61(5):501-13.

  2. Falk E. Pathogenesis of Atherosclerosis. J Am Coll Cardiol. 2006;47(8):7-12.

  3. Badimón JJ, Ibañez B. Incremento de las HDL como arma terapéutica en la aterotrombosis. Rev Esp Cardiol. 2010;63(3):323-33.

  4. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atheros-clerosis: the ASTEROID trial. JAMA. 2006;295(13): 1556-65.

  5. Pérez Méndez O. Lipoproteínas de alta densidad (HDL). ¿Un objetivo terapéutico en la prevención de la aterosclerosis? Arch Cardiol Mex. 2004;74(1): 53-67.

  6. Toth P. The "good cholesterol": high-density lipo-protein. Circulation. 2005;111(5):e89-91.

  7. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoof-nagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement ac-tivation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746-56.

  8. Lewis GF, Rader DJ. New insights into the regul-ation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-32.

  9. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116(4): 1052-62.

  10. 10.Yokoyama S. ABCA1 and biogenesis of HDL. J Athe-roscler Thromb. 2006;13(1):1-15.

  11. Yvan-Charvet L, Pagler TA, Wang N, Senokuchi T, Brundert M, Li H, et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plas-ma HDL. J Lipid Res. 2008;49(1):107-14.

  12. 12.Wang N, Collins HL, Ranalletta M, Fuki IV, Billhei-mer JT, Rothblat GH, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage re-verse cholesterol transport in vivo. J Clin Invest. 2007;117(8):2216-24.

  13. 13.Curtiss LK, Volenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse choles-terol transport? Arterioscler Thromb Vasc Biol. 2006;26(1):12-9.

  14. 14.Cuchel M, Rader DJ. Macrophage reverse choles-terol transport: key to the regression of Atheros-clerosis? Circulation. 2006;113(21):2548-55.

  15. 15.Shah PK. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J. 2007;28(1):5-12.

  16. 16.Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22.

  17. 17.Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116(12):3090-100.

  18. 18.Mackness B, Hine D, Liu Y, Mastorikou M, Mack-ness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Bio-chem Biophys Res Commun. 2004;318(3):680-3.

  19. 19.Tomás M, Latorre G, Sentí M, Marrugat J. Función antioxidante de las lipoproteínas de alta densidad: un nuevo paradigma en la arteriosclerosis. Rev Esp Cardiol. 2004;57(6):557-69.

  20. 20.Assmann G, Gotto AM. HDL Cholesterol and Pro-tective Factors in Atherosclerosis. Circulation. 2004; 109(23 Suppl 1):III8-14.

  21. 21.Mineo C, Deguchi H, Griffin JH, Shaul PW. Endo-thelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352-64.

  22. 22.Gharavi NM, Baker NA, Mouillesseaux KP, Yeung W, Honda HM, Hsieh X, et al. Role of endothelial nitric oxide synthase in the regulation of SREBP acti-vation by oxidized phospholipids. Circ Res. 2006; 98(6): 768-76.

  23. 23.Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest. 2004;113(4): 509-13.

  24. 24.Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipo-protein AI increase endothelial NO synthase activity by protein association and multisite phosphoryl-ation. Proc Natl Acad Sci USA. 2004;101(18):6999-7004.

  25. 25.Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278(11):9142-9.

  26. 26.Nofer JR, van der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski K, Baba HA, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113(4):569-81.

  27. 27.Blankenberg S, Barbaux S, Tiret L. Adhesion mole-cules and atherosclerosis. Atherosclerosis. 2003; 170(2):191-203.

  28. 28.Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94(6):706-14.

  29. 29.Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238(1):61-5.

  30. 30.Sugano M, Tsuchida K, Makino N. High-density li-poproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem Biophys Res Commun. 2000;272(3):872-6.

  31. 31.Dimmeler S, Haendeler J, Zeiher AM. Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol. 2002;13(5):531-6.

  32. 32.Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical character-istics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001;33(9):1673-90.

  33. 33.Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001;276(37):34480-5.

  34. 34.Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endo-thelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol. 2001;167(5):2831-8.

  35. 35.Linton MF, Fazio S. Cyclooxygenase-2 and atheros-clerosis. Curr Opin Lipidol. 2002;13(5):497-504.

  36. 36.Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacy-clin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol. 2004;24(5):871-7.

  37. 37.Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atheros-clerosis. Cell Metabolism. 2008;7(5):365-75.

  38. 38.Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 2003;54: 321-41.

  39. 39.Durand E, Scoazec A, Lafont A, Boddaert J, Al Haj-zen A, Addad F, et al. In vivo induction of endo-thelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the under-standing of the mechanisms of thrombotic plaque erosion. Circulation. 2004;109(21):2503-6.

  40. 40.Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005;3(8):1590-6.

  41. 41.Deguchi H, Yegneswaran S, Griffin JH. Sphingolipids as bioactive regulators of thrombin generation. J Biol Chem. 2004;279(13):12036-42.

  42. 42.Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma bio-markers in the prediction of first atherothrombotic events. Circulation. 2004;109(25 Suppl 1):IV6-19.

  43. 43.Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, et al. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br J Haematol. 2004;127(1):97-104.

  44. 44.Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, Rye KA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol. 2006;48(4):715-20.

  45. 45.Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, et al. Effects of the amount and intensity of exercise on plasma lipo-proteins. N Engl J Med. 2002;347(19):1483-92.

  46. 46.Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Oni-take F, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein choles-terol: a meta-analysis. Arch Intern Med. 2007; 167(10):999-1008.

  47. 47.Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7):786-98.

  48. 48.Dattilo AM, Kris-Etherton PM. Effects of weight re-duction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320-8.

  49. 49.Garrison RJ, Kannel WB, Feinleib M, Castelli WP, McNamara PM, Padgett SJ. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis. 1978;30(1):17-25.

  50. 50.Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003;37(4):283-90.

  51. 51.Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocar-dial infarction. N Engl J Med. 1993;329(25):1829-34.

  52. 52.Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA, Stampfer MJ, Willett WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med. 2003;348(2):109-18.

  53. 53.Santos-Gallego CG, Ibanez B, Badimon JJ. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol. 2008;76(4): 443-52.

  54. 54.Badimón JJ, Santos-Gallego CG, Badimón L. Impor-tancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos? Rev Esp Cardiol. 2010;63(2):20-35.

  55. 55.Jones PH, Davidson MH, Stein EA, Bays HE, Mc-Kenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvas-tatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-60.

  56. 56.Schaefer JR, Schweer H, Ikewaki K, Stracke H, Sey-berth HJ, Kaffarnik H, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I in-crease by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis. 1999;144(1):177-84.

  57. 57.Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer pro-tein inhibitors. Eur Heart J. 2010;31(2):149-64.

  58. 58.Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-18.

  59. 59.Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Piogli-tazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-8.

  60. 60.Willemen MJ, Mantel-Teeuwisse AK, Buggy Y, Lay-ton D, Straus SM, Leufkens HG, et al. Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study. Drug Saf. 2012;35(12):1147-58.

  61. 61.Zelcer N, Tontonoz P. Liver X receptors as inte-grators of metabolic and inflammatory signaling. J Clin Invest. 2006;116(3):607-14.

  62. 62.Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in pa-tients with acute coronary syndromes: a random-ized controlled trial. JAMA. 2003;290(17):2292-300.

  63. 63.Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesper-ance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675-82.

  64. 64.Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008; 103(10):1084-91.

  65. 65.Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipo-protein levels. Curr Opin Cardiol. 2009;24(5):473-82.

  66. 66.Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, No-rris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008;49(6):1344-52.




2020     |     www.medigraphic.com